J&J's Ortho enjoined
From the sale of "any female contraceptive product containing the chemical compound norgestimate" by a Philadelphia federal court pending a full trial or the expiration of American Home Products' patent on norgestrel on Jan. 11, 1994. The Nov. 25 decision came the day before the expiration of another AHP patent on norgestrel, and at the end of a Feb. 23, 1990 injunction that prevented Ortho from selling any norgestimate-containing products because Ortho's Ortho-Cyclen was found to infringe AHP's patent ("The Pink Sheet" March 5, 1990, T&G-10). The current decision holds that Ortho's product infringes a clause of a later AHP patent covering the use of norgestrel.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth